(Q42139962)

17 October 2017

Reappraisal of glucocorticoids in castrate-resistant prostate cancer (English)

1 reference

17 October 2017

3

Johann de Bono

1 reference

17 October 2017

Oliver Sartor

1

1 reference

PMCID

4215665

17 October 2017

Christopher C Parker

series ordinal

2

1 reference

17 October 2017

1 September 2014

1 reference

Asian Journal of Andrology

17 October 2017

1 reference

17 October 2017

16

1 reference

17 October 2017

5

1 reference

17 October 2017

666

1 reference

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade

17 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215665

The changing therapeutic landscape of castration-resistant prostate cancer

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215665

A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215665

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215665

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215665

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215665

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215665

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215665

Steroid receptors aplenty in prostate cancer

17 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24994787

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4103/1008-682X.133314

1 reference

17 October 2017

1 reference

17 October 2017

1 reference

PMCID

4215665